Premium
Phase II evaluation of paclitaxel, α‐interferon, and cis ‐retinoic acid in advanced renal cell carcinoma
Author(s) -
Vaishampayan Ulka,
Flaherty Lawrence,
Du Wei,
Hussain Maha
Publication year - 2001
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(20010801)92:3<519::aid-cncr1350>3.0.co;2-#
Subject(s) - medicine , renal cell carcinoma , retinoic acid , paclitaxel , interferon , cancer research , carcinoma , oncology , chemotherapy , virology , cell culture , genetics , biology
BACKGROUND Interferon and 13‐ cis ‐retinoic acid (13‐CRA) therapy showed clinical response rates of 30% in advanced renal cell carcinoma (RCC). This combination also enhanced sensitivity to paclitaxel in a bcl‐2 and mutant p53 expressing renal carcinoma cell line. Based on this, the authors conducted a Phase II clinical trial of the combination of interferon, 13‐CRA, and weekly paclitaxel, in advanced RCC. METHODS The eligibility criteria consisted of unresectable or metastatic RCC, measurable disease, a Southwest Oncology Group performance status of 0–2, and adequate bone marrow, hepatic, and renal function. Prior cytotoxic or immunologic treatment including interferon was permitted. Paclitaxel was administered at a dose of 80 mg/m 2 as a 1‐hour intravenous infusion on Days 1, 8, and 15 of each 28‐day cycle. Interferon was administered at a dose of 3 million units subcutaneously daily and 13‐CRA at 1 mg/kg/day orally in 2 divided doses for the first 21 days of each cycle. RESULTS Twenty‐one patients were enrolled with a median age of 52 years, 16 males and 5 females, 10 patients with no prior therapy, 5 each with prior interleukin‐2 or interferon therapy, and 1 patient with both. Four patients had also received prior investigational chemotherapy. A total of 61cycles were administered with a median of 2 per patient. Grade 3 and 4 toxicities were neutropenia in three patients, anemia in four patients, and asthenia, skin rash, and hypersensitivity reaction in one case each. Of the 20 evaluable patients, one objective partial response was observed for a duration of 7+ months. Seven patients had disease stabilization. The median survival of the entire population was 9.5 months (range, 4–18+ months). CONCLUSIONS The combination of 13‐CRA, interferon, and weekly paclitaxel was well tolerated and had minimal efficacy in advanced RCC. Cancer 2001;92:519–23. © 2001 American Cancer Society.